Department of Paediatric Haematology and Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Department of Paediatric Haematology and Oncology, Great North Children's Hospital, Newcastle upon Tyne, UK.
Arch Dis Child. 2020 Mar;105(3):247-252. doi: 10.1136/archdischild-2019-317245. Epub 2019 Oct 8.
Patients with central nervous system germ cell tumours (CNS-GCTs) commonly initially present to primary care or general paediatricians. Prolonged symptom intervals (SI) are frequently seen in CNS-GCTs and have been associated with inferior outcomes in other brain tumours. This study reviewed the clinical presentation of CNS-GCTs and examined the effect of prolonged SI.
DESIGN/SETTING/PATIENTS/OUTCOMES: International multicentre 10-year retrospective study (2002-2011 inclusive), across six international paediatric oncology treatment centres. All newly diagnosed patients with CNS-GCT were included. Main outcome measure was time interval from first symptom to diagnosis.
The study cohort included 86 (58 males:28 female) patients (59 'germinoma' and 27 'non-germinomatous' GCTs), with tumours being pineal (n=33), suprasellar (n=25), bifocal (pineal+suprasellar; n=24) and 'other' site (n=4), of which 16 (19%) were metastatic. Median age at diagnosis was 14 years (0-23 years). The time to diagnosis from first symptom (SI) was 0-69 months (median 3 months, mean 9 months). A prolonged SI (>6 months) was observed in 28/86 patients (33%) and significantly associated with metastatic disease (11/28 (39%) vs 5/58 (9%); p=0.002)) at diagnosis, but not overall survival. With prolonged SI, endocrine symptoms, particularly diabetes insipidus, were more common (21/28 (75%) vs 14/58 (24%) patients; p<0.002), but raised intracranial pressure (RICP) was less frequent (4/28 (14%) vs 43/58 (74%) patients; p<0.001)) at first symptom.
One-third of patients with CNS-GCT have >6 months of symptoms prior to diagnosis. Delayed diagnosis is associated with metastatic disease. Early symptom recognition, particularly related to visual and hormonal disturbances in the absence of RICP, may improve timely diagnosis, reduce metastatic disease frequency and consequently reduce treatment burden and late effects.
中枢神经系统生殖细胞瘤(CNS-GCT)患者通常最初就诊于初级保健医生或儿科医生。在 CNS-GCT 中经常出现较长的症状间隔(SI),并且与其他脑肿瘤的不良预后相关。本研究回顾了 CNS-GCT 的临床表现,并研究了延长 SI 的影响。
设计/设置/患者/结果:这是一项国际多中心 10 年回顾性研究(2002-2011 年),涉及 6 个国际儿科肿瘤治疗中心。所有新诊断的 CNS-GCT 患者均纳入研究。主要观察指标是从首发症状到诊断的时间间隔。
研究队列包括 86 名(58 名男性:28 名女性)患者(59 名“生殖细胞瘤”和 27 名“非生殖细胞瘤”GCT),肿瘤位于松果体(n=33)、鞍上(n=25)、双灶(松果体+鞍上;n=24)和“其他”部位(n=4),其中 16 例(19%)为转移性肿瘤。诊断时的中位年龄为 14 岁(0-23 岁)。从首发症状到诊断的时间(SI)为 0-69 个月(中位数 3 个月,平均 9 个月)。28/86 例(33%)患者 SI 延长(>6 个月),且与诊断时的转移性疾病显著相关(11/28(39%)与 5/58(9%);p=0.002),但与总体生存无关。在 SI 延长的患者中,内分泌症状,特别是尿崩症更为常见(21/28(75%)与 14/58(24%)患者;p<0.002),但颅内压升高(RICP)较少见(4/28(14%)与 43/58(74%)患者;p<0.001))。
三分之一的 CNS-GCT 患者在诊断前有超过 6 个月的症状。延迟诊断与转移性疾病相关。早期症状识别,特别是在没有 RICP 的情况下,与视觉和激素紊乱相关,可能会改善及时诊断,降低转移性疾病的发生率,并降低治疗负担和迟发性影响。